Biology and management of chronic graft-versus-host disease

Cancer Treatment and Research

Volumn 144, Issue , 2009, Pages 277-298

  Martin, Paul J ^a   Pavletic, Steven Z ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BORTEZOMIB; CLOFAZIMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; ETRETIN; HYDROXYCHLOROQUINE; IMATINIB; IMMUNOGLOBULIN; INFLIXIMAB; MONTELUKAST; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; URSODEOXYCHOLIC ACID;

B LYMPHOCYTE; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEPIGMENTATION; DRUG DOSE REDUCTION; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOBIOLOGY; LABORATORY TEST; LUNG FUNCTION TEST; LYMPH NODE IRRADIATION; MORNING DOSAGE; MYOPATHY; NAIL DYSTROPHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PUVA; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; SKIN BIOPSY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77953658720     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78580-6_12     Document Type: Review

References (107)

1. Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol. 1978;91:545-570
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-233
3. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005;11:945-956
4. ShulmanHM, KleinerD, Lee SJ,Morton T, Pavletic SZ, Farmer E,Moresi JM,Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. PathologyWorking Group Report. Biol Blood Marrow Transplant. 2006;12:31-47. (Pubitemid 43034096)
5. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006; 12:126-137 (Pubitemid 43138008)
6. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252-266 (Pubitemid 43273710)
7. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK,Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375-396
8. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006; 12:491-505.
9. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409-417
10. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007;13:1207-1215
11. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69: 204-217
12. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM. Severity of chronic graft-versus-host disease: association with treatment- related mortality and relapse. Blood 2002;100:406-414
13. Akpek G, Zahurak ML, Piantadosi S,Margolis J, Doherty J, Davidson R, Vogelsang GB. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001;97:1219-1226 (Pubitemid 32183742)
14. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu A, Horowitz MM, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003;102:802-809
15. Arora M, Burns LJ, Davies SM, Macmillan ML, Defor TE, Miller WJ, Weisdorf DJ. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant. 2003;9:38-45.
16. Pavletic SZ,Carter SL, KernanNA,Henslee-Downey J,MendizabalAM, Papadopoulos E, Gingrich R, Casper J, Yanovich S, Weisdorf D. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005;106:3308-3313
17. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583-594
18. Nikolic B, Lee S, Bronson RT, GrusbyMJ, SykesM. Th1 and Th2 mediate acute graftversus- host disease, each with distinct end-organ targets. J Clin Invest. 2000;105: 1289-1298
19. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J, Gressner AM, Matern S, Lammert F. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet. 2005;37:835-843
20. Niculescu F, Niculescu T, Nguyen P, Puliaev R, Papadimitriou JC, Gaspari A, Rus H, Via CS. Both apoptosis and complement membrane attack complex deposition are major features of murine acute graft-vs.-host disease. Exp Mol Pathol. 2005;79: 136-145
21. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol. 1986;136:3543-3548
22. Ghayur T, Seemayer TA, Xenocostas A, Lapp WS. Complete sequential regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease. Am J Pathol. 1988;133:39-46.
23. Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, Onoe K. Abrogation of negative selection by GvHR induced by minor histocompatibility antigens or H-2D antigen alone. Immunobiology 2000;202:268-279
24. Zhang Y, Hexner E, Frank D, Emerson SG. CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol. 2007;179:3305-3314
25. Marguerat S, MacDonald HR, Kraehenbuhl JP, van Meerwijk JP. Protection from radiation-induced colitis requiresMHCclass II antigen expression by cells of hemopoietic origin. J Immunol. 1999;163:4033-4040
26. Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood 2003;102:429-435
27. Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M, Tanimoto M, Teshima T. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 2007;109:1756-1764
28. Tsoi MS, Storb R, Dobbs S, Medill L, Thomas ED. Cell-mediated immunity to non-HLA antigens of the host by donor lymphocytes in patients with chronic graft-vs-host disease. J Immunol. 1980;125:2258-2262
29. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GvHD) as a model for scleroderma. I. Description of model systems. Cell Immunol. 1983;77:1-12.
30. Claman HN, Jaffee BD, Huff JC, Clark RA. Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol. 1985;94:73-84.
31. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graftversus- host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum. 2004;50:1319-1331
32. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687-1698
33. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, Shlomchik WD. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101-108
34. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693-5699
35. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005;105:2227-2234
36. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graftversus- host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088-3098
37. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression byDNAmicroarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2007;127:281-292
38. Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2003;121:713-719
39. Freund YR, Sgarlato G, Jacob CO, Suzuki Y, Remington JS. Polymorphisms in the tumor necrosis factor alpha (TNF-alpha) gene correlate with murine resistance to development of toxoplasmic encephalitis and with levels of TNF-alpha mRNA in infected brain tissue. J Exp Med. 1992;175:683-688
40. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated selfreactivity. Nat Rev Immunol. 2007;7:443-453
41. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Chen D, Zhang H, Ding Y, Bromberg JS. TGF-beta induces Foxp3+ T-regulatory cells from CD4+CD25- precursors. Am J Transplant. 2004;4:1614-1627
42. MacDonald KP, Rowe V, Filippich C, Johnson D, Morris ES, Clouston AD, Ferrara JL, Hill GR. Chronic graft-versus-host disease after granulocyte colony-stimulating factormobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation. Biol Blood Marrow Transplant. 2004;10:373-385
43. Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A, Kelly J, Ledbetter S, Clouston AD, Hill GR. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106:2206-2214
44. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999;67:59-65.
45. Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, Cho CR, Cameron MJ, Kelvin DJ, Chagnon P, Roy DC, Busque L, Sekaly RP, Perreault C. Prediction of graftversus- host disease in humans by donor gene-expression profiling. PLoS Med. 2007;4:e23.
46. Kim J, Kim HJ, Park K, Kim J, Choi HJ, Yagita H, Nam SH, Cho HR, Kwon B. Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. Blood 2007;110:776-782
47. Tsoi MS, Storb R, JonesE,Weiden PL, ShulmanH,Witherspoon R, Atkinson K, Thomas ED. Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol. 1978;120:1485-1492
48. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, Strober S, Zeng D. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993-3001.
49. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 1988;46:238-240 (Pubitemid 18204037)
50. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756-762 (Pubitemid 44061381)
51. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, Reid GS, Wall D, Goldman F, Schultz KR. Altered toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:386-397
52. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, Moroncini G, Bacigalupo A, Leoni P, Avvedimento EV, Gabrielli A. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007;110:237-241
53. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004;104:1565-1573
54. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood 2005;105:4885-4891
55. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune- mediated pathology in chronic graft-versus-host disease. Blood 2007;110:3804-3813
56. Fujita S, Sato Y, Sato K, Eizumi K, Fukaya T, Kubo M, Yamashita N, Sato K. Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells. Blood 2007;110:3793-3803
57. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004;104:2187-2193
58. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106:2903-2911
59. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, Miehlke S, BornhauserM, Schneider T, ZeitzM, SteinH, Thiel E,DuchmannR,Uharek L. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronicGvHD. Blood 2006;107:1717-1723
60. Meignin V, Peffault de Latour R, Zuber J, Regnault A, Mounier N, Lemaitre F, Dastot H, Itzykson R, Devergie A, Cumano A, Gluckman E, Janin A, Bandeira A, Socie G. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of longterm tolerance after allogeneic stem cell transplantation. Exp Hematol. 2005;33: 894-900.
61. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graftversus- host disease after allogeneic stem cell transplantation. Int J Hematol. 2007;85: 154-162
62. Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and marrow transplant clinical trials network state of the science symposium 2007. Biol Blood Marrow Transplant. 2007;13:1268-1285 (Pubitemid 47576946)
63. Storb R,DeegHJ, Pepe M, Doney K, AppelbaumF, Beatty P, BensingerW, Buckner CD, CliftR,Hansen J, et al. Graft-versus-host disease prevention bymethotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol. 1989;72:567-572 (Pubitemid 19220499)
64. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K, Martin P, Stewart P, Sullivan KM, Witherspoon R, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood. 1990;76: 1037-1045
65. Ross M, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Forman SJ, Blume KG, Chao NJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Biol Blood Marrow Transplant. 1999;5:285-291
66. Ringden O, Paulin T, Lonnqvist B, Nilsson B. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol. 1985;13:1062-1067
67. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303-2314
68. Kansu E, Gooley T, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001;98:3868-3870
69. Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD, Nademanee AP, Negrin RS, Snyder DS, Hu WW, Gould KA, Tierney DK, Zwingenberger K, Forman SJ, Blume KG. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol BloodMarrow Transplant. 1996;2:86-92.
70. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C, Appelbaum FR, Bowden RA, Buckner CD, Crawford SW, Deeg HJ, Hansen JA, McDonald GB, Sanders JE, Storb R. A controlled trial of longterm administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant. 1996;2:44-53.
71. Loughran TP Jr, Sullivan K, Morton T, Beckham C, Schubert M, Witherspoon R, Sale G, Sanders J, Fisher L, Shulman H, et al. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990;76:228-234
72. Fong T, Trinkaus K,Adkins D,VijR,Devine SM, TomassonM, GoodnoughLT, Lopez S, Graubert T, Shenoy S, Dipersio JF, Khoury HJ. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:1201-1206
73. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-4590
74. Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol. 2005;12:457-462
75. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA,Appelbaum FR, Carpenter PA, Sanders JE, Kiem HP, Nash RA, Petersdorf EW, Moravec C, Morton AJ, Anasetti C, Flowers ME, Martin PJ. Duration of immunosuppressive treatment for chronic graftversus- host disease. Blood 2004;104:3501-3506
76. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72:546-554
77. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988;72: 555-561
78. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Storb R, Appelbaum FR, Martin PJ. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48-51.
79. Flowers ME, Lee S, Vogelsang G. An update on how to treat chronic GVHD. Blood 2003;102:2312.
80. Wingard JR, Piantadosi S, VogelsangGB, Farmer ER, JabsDA, Levin LS, Beschorner WE, Cahill RA,Miller DF, Harrison D, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989;74:1428-1435 (Pubitemid 19227458)
81. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000;96:3995-3996
82. AroraM,Wagner JE,Davies SM,Blazar BR, DeforT, Enright H, MillerWJ,WeisdorfDF. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7:265-273
83. Giaccone L, Martin P, Carpenter P,Moravec C,HooperH, Funke VA, Storb R, FlowersME. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versushost disease. Bone Marrow Transplant. 2005;36:337-341
84. Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant. 2006;37:95-99
85. VogelsangGB, Farmer ER,Hess AD, Altamonte V, BeschornerWE, Jabs DA, Corio RL, Levin LS, Colvin OM,Wingard JR, et al. Thalidomide for the treatment of chronic graftversus- host disease. N Engl J Med. 1992;326:1055-1058
86. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graftversus- host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:517-520
87. Lopez F, Parker P,NademaneeA,RodriguezR,Al-Kadhimi Z, BhatiaR, Cohen S, Falk P, Fung H, Kirschbaum M, Krishnan A, Kogut N, Molina A, Nakamura R, O'Donnell M, Popplewell L, Pullarkat V, Rosenthal J, Sahebi F, Smith E, SnyderD, Somlo G, Spielberger R, Stein A, Sweetman R, Zain J, Forman S. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:307-313
88. Carnevale-Schianca F, Martin P, Sullivan K, Flowers M, Gooley T, Anasetti C, Deeg J, Furlong T, McSweeney P, Storb R, Nash RA. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:613-620
89. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant. 2006;12:37-40.
90. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolanos-Meade J, et al.A phase II study of pentostatin in patiens with steroid-refractory shronic graft-versus-host disease. J Clin Oncol. 2007;25:4255-4261
91. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, Scime R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R. Treatment of refractory chronic GvHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273-277
92. Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, Cirenza E, Mazumder A, Gehan E, Cahill R, Frankel S, Schultz K. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:327-334
93. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7:495-502.
94. Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, Horn T. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 1996;17:1061-1067
95. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Spielberger R, Somlo G, Margolin K, Zwingenberger K, Wilsman K, Negrin RS, Long GD, Niland JC, Blume KG, Forman SJ. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-3609
96. Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med. 1992;116:624-629
97. Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH. Treatment of chronic graftversus- host disease with clofazimine. Blood 1997;89:2298-2302
98. Marcellus DC, Altomonte VL, Farmer ER, Horn TD, Freemer CS, Grant J, Vogelsang GB. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999;93:66-70.
99. Robin M, Guardiola P, Girinsky T, Hernandez G, Esperou H, Ribaud P, Rocha V, Garnier F, Socie G, Gluckman E, Devergie A. Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005;80:634-642
100. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab- daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer. 2007;49:212-215
101. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graftversus- host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45-52.
102. Arat M, Ilhan O, Iayan EA, Celebi H, Koc H, Akan H. Treatment of extensive chronic sclerodermatous graft-versus-host disease with high-dose immunosuppressive therapy and CD34+ autologous stem cell rescue. Blood 2001;98:892-893
103. Mayer J, Krejci M, Doubek M, Pospisil Z, Brychtova Y, Tomiska M, Racil Z. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant. 2005;35:699-705.
104. Majhail NS, Schiffer CA, Weisdorf DJ. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:789-791
105. Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M, Sacks Z, Shapira MY. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007;83:577-581
106. Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, Horowitz MM, Akpek G, Flowers ME, Couriel D, Martin PJ. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8:32-39
107. Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005;78:265-274